Healthcare & Medical Devices Global On demand · 24-48h

Global Endocrine Disrupting Properties Assessment Market Strategic Research Report

Global Endocrine Disrupting Properties Assessment Market Str…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Endocrine Disrupting Properties Assessment Market
$2042025
6.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: In Vitro (Cell-based) Testing, In Vivo (Animal) Testing, In Silico (Computational) Modeling, Others

By Application: Environmental Monitoring, Food Safety, Cosmetics and Personal Care Products, Public Health and Disease Prevention, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Labcorp, Eurofins Scientific, Intertek, Charles River Laboratories, PerkinElmer, Smithers, Fera Science, Staphyt, TransGenic, ToxStrategies, LAUS, Creative Bioarray, Creative Proteomics, Compliance Services International, Xenometrix, Shenyang SYRICI Testing

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 125 pages
Market size 2025
$204
Million USD
Forecast CAGR
6.8%
2025-2032
Forecast 2032
$323.3
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Endocrine Disrupting Properties Assessment market size is predicted to grow from US$ 204 million in 2025 to US$ 320 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.

Endocrine Disrupting Properties Assessment refers to the scientific and regulatory evaluation of whether a chemical substance, mixture, ingredient, material or active substance has properties that may interfere with the endocrine system and lead to adverse effects in humans or the environment. The assessment typically integrates existing toxicological data, endocrine activity screening, mechanistic evidence, apical adverse-effect studies, exposure and relevance considerations, and a weight-of-evidence judgement based on recognized regulatory frameworks and test guidelines. In market terms, it covers laboratory testing, data gap analysis, study design, dossier review, expert interpretation and compliance support for chemicals, pesticides, biocides, cosmetics ingredients, industrial materials and other regulated substances. OECD guidance focuses on standardized test guidelines for evaluating chemicals for endocrine disruption, including estrogen, androgen, thyroid and steroidogenesis-related modalities, while EU regulatory frameworks have established scientific criteria for identifying endocrine disruptors in biocidal and plant protection product areas.

The Endocrine Disrupting Properties Assessment market is becoming an increasingly important segment of chemical safety, regulatory toxicology and compliance testing services. Demand is mainly driven by stricter regulatory attention to chemicals that may interfere with hormonal systems, especially under European chemical, biocidal product and plant protection product frameworks. The market is not limited to a single laboratory test, but combines in vitro screening, in vivo toxicology data, mechanistic interpretation, weight-of-evidence evaluation, regulatory dossier preparation and expert review. Service providers with strong experience in OECD test guidelines, ECHA and EFSA guidance, REACH, CLP, biocides, pesticides and cosmetics-related compliance are likely to gain advantages, because customers need not only test results, but also defensible scientific conclusions that can support product registration, substance approval, risk assessment and market access. OECD describes its work as supporting countries’ needs for testing and assessment of chemicals for endocrine disrupters, while ECHA maintains an endocrine disruptor assessment process and list for substances under assessment.

This report presents a comprehensive overview of the global Endocrine Disrupting Properties Assessment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • In Vitro (Cell-based) Testing
  • In Vivo (Animal) Testing
  • In Silico (Computational) Modeling
  • Others

Segment by Endocrine Pathway

  • Estrogen Pathway Assessment
  • Androgen Pathway Assessment
  • Thyroid Pathway Assessment
  • Steroid Synthesis Pathway Assessment
  • Others

Segment by Application

  • Environmental Monitoring
  • Food Safety
  • Cosmetics and Personal Care Products
  • Public Health and Disease Prevention
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Endocrine Disrupting Properties Assessment market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Environmental Monitoring, Food Safety, Cosmetics and Personal Care Products evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Endocrine Disrupting Properties Assessment Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$204
2025
Forecast
$323.3
2032
CAGR
6.8%
2025–2032
Области
5
global
Key companies
LabcorpEurofins ScientificIntertekCharles River LaboratoriesPerkinElmerSmithersFera ScienceStaphyt
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
In Vitro (Cell-based) TestingIn Vivo (Animal) TestingIn Silico (Computational) ModelingOthers
By Application
Environmental MonitoringFood SafetyCosmetics and Personal Care ProductsPublic Health and Disease PreventionOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 In Vitro (Cell-based) Testing
  • 3.1.3 In Vivo (Animal) Testing
  • 3.1.4 In Silico (Computational) Modeling
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Environmental Monitoring
  • 4.1.3 Food Safety
  • 4.1.4 Cosmetics and Personal Care Products
  • 4.1.5 Public Health and Disease Prevention
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Labcorp
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Eurofins Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Intertek
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Charles River Laboratories
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 PerkinElmer
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Smithers
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Fera Science
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Staphyt
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 TransGenic
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 ToxStrategies
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 LAUS
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Creative Bioarray
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Creative Proteomics
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Compliance Services International
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Xenometrix
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Shenyang SYRICI Testing
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Endocrine Disrupting Properties Assessment market?
The global Endocrine Disrupting Properties Assessment market is estimated at US$ 204 million in 2025 (base year) and is projected to reach US$ 320 million by 2032.
What is the forecast CAGR for the Endocrine Disrupting Properties Assessment market?
The market is expected to grow at a CAGR of 6.8% from 2026 to 2032, expanding from US$ 204 million in 2025 to US$ 320 million in 2032, roughly 1.6 times its base-year value.
What is Endocrine Disrupting Properties Assessment?
Endocrine Disrupting Properties Assessment refers to the scientific and regulatory evaluation of whether a chemical substance, mixture, ingredient, material or active substance has properties that may interfere with the endocrine system and lead to adverse effects in humans or the environment. In market terms, it covers laboratory testing, data gap analysis, study design, dossier review, expert interpretation and compliance support for chemicals, pesticides, biocides, cosmetics ingredients, industrial materials and other regulated substances.
How is the Endocrine Disrupting Properties Assessment market segmented by type?
By type, the market is segmented into In Vitro (Cell-based) Testing, In Vivo (Animal) Testing, In Silico (Computational) Modeling and Others.
What are the key applications of Endocrine Disrupting Properties Assessment?
Key applications covered include Environmental Monitoring, Food Safety, Cosmetics and Personal Care Products, Public Health and Disease Prevention and Others.
Which companies are profiled in the Endocrine Disrupting Properties Assessment market report?
Key players profiled include Labcorp, Eurofins Scientific, Intertek, Charles River Laboratories, PerkinElmer, Smithers, Fera Science and Staphyt, among 16 companies covered in total.
What geographies does the Endocrine Disrupting Properties Assessment market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Endocrine Disrupting Properties Assessment?
Demand is mainly driven by stricter regulatory attention to chemicals that may interfere with hormonal systems, especially under European chemical, biocidal product and plant protection product frameworks.
Who should buy the Endocrine Disrupting Properties Assessment market report?
The report is intended for manufacturers and solution providers, distributors and end users in Environmental Monitoring, Food Safety and Cosmetics and Personal Care Products, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Endocrine Disrupting Properties Assessment market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.